Company · RAPP
Rapport Therapeutics, Inc.
Nasdaq's symbol directory lists RAPP on Nasdaq as “Rapport Therapeutics, Inc. - Common Stock”.
In the 12 months to Nov 8, 2026: insiders bought on 7 occasions ($22.0M); insiders sold on 16 occasions ($8.1M); 2 planned-sale notices; 3 filings by holders of 5% or more; 3 company reports (Form 8-K, since May 26, 2026).
All insider filings at the SEC · Appeared in No. 38, No. 37, No. 36, No. 35, No. 34, No. 33, No. 32, No. 31
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- HEALY JAMES bought $20.4M
- Ceesay Abraham, Chief Executive Officer sold $4.8M
- Yeleswaram Krishnaswamy, Chief Development Officer sold $2.6M
- PAUL STEVEN M bought $974K
- Gault Cheryl, Chief Operating Officer sold $748K
- John Maraganore bought $249K
- Troy A. Ignelzi, Chief Financial Officer bought $144K
- Young Wendy B. bought $100K
- Silva Paul M bought $100K
- Sanchez Ramiro bought $98K
Every trade (23)
- BUYHEALY JAMES bought $20.4M
- BUYSanchez Ramiro bought $98K
- BUYPAUL STEVEN M bought $974K
- BUYJohn Maraganore bought $249K
- BUYYoung Wendy B. bought $100K
- BUYSilva Paul M bought $100K
- BUYTroy A. Ignelzi, Chief Financial Officer bought $144K
- SELLCeesay Abraham, Chief Executive Officer sold $64K
- SELLCeesay Abraham, Chief Executive Officer sold $35K
- SELLCeesay Abraham, Chief Executive Officer sold $108K
- SELLGault Cheryl, Chief Operating Officer sold $332K
- SELLCeesay Abraham, Chief Executive Officer sold $87K
- SELLCeesay Abraham, Chief Executive Officer sold $374K
- SELLYeleswaram Krishnaswamy, Chief Development Officer sold $1.9M
- SELLCeesay Abraham, Chief Executive Officer sold $938K
- SELLYeleswaram Krishnaswamy, Chief Development Officer sold $658K
- SELLYeleswaram Krishnaswamy, Chief Development Officer sold $20K
- SELLCeesay Abraham, Chief Executive Officer sold $1.4M
- SELLCeesay Abraham, Chief Executive Officer sold $1.0M
- SELLCeesay Abraham, Chief Executive Officer sold $93K
- SELLCeesay Abraham, Chief Executive Officer sold $328K
- SELLGault Cheryl, Chief Operating Officer sold $416K
- SELLCeesay Abraham, Chief Executive Officer sold $327K
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- Abraham N. Ceesay $1.2M
- CHERYL GAULT $330K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- Third Rock Ventures V, L.P. 13.1%
- Cormorant Asset Management, LP 5.56%
- Capital International Investors 6.1%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition Nov 4, 2026
- Entry into a material definitive agreement; Results of operations and financial condition; Creation of a direct financial obligation; Unregistered sales of equity securities Oct 30, 2026
- Regulation FD disclosure; Other events Oct 20, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.